| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate |
1998-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab38dae9db4d71429c3d87483de21009 |
| publicationDate |
2003-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1317929-A2 |
| titleOfInvention |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection |
| abstract |
There is disclosed the use of ribavirin, interferon alpha or ancombination of ribavirin and interferon alpha for the manufacture of anpharmaceutical composition for treating a patient having chronic hepatitisnC infection to eradicate detectable HCV-RNA by a method comprisingnadministering an effective amount of ribavirin in association with anneffective amount of interferon alpha, wherein the patient is one havingnfailed to respond to a previous course of interferon alpha therapy. Thencompositions may be used in a method for treating a patient havingnchronic hepatitis C infection to eradicate detectable HCV-RNA involvingna combination therapy using a therapeutically effective amount ofnribavirin and a therapeutically effective amount of interferon-alpha for antime period of from 20 up to 80 weeks. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8137661-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8993517-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9221896-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9296809-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7785599-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7847079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005016370-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8252739-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8513189-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8071539-B2 |
| priorityDate |
1997-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |